Zymeworks and Merck collaborate on "bispecific" antibodies

08/29/2011 | Xconomy

Canada's Zymeworks agreed to partner with Merck & Co. to develop "bispecific" antibody drugs for cancer and autoimmune conditions. The deal entitles Zymeworks to as much as $187 million in upfront and milestone fees, plus tiered royalties. Merck will gain exclusive global rights to market resulting therapies.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX